Zobrazit více v PubMed
ABEL A, STEEG C, AMINKIAH F, ADDAI-MENSAH O, ADDO M, GAGLIANI N, CASAR C, YAR DD, OWUSU-DABO E, JACOBS T, MACKROTH MS. Differential expression pattern of co-inhibitory molecules on CD4+ T cells in uncomplicated versus complicated malaria. Sci Rep. 2018;8:4789. doi: 10.1038/s41598-018-22659-1.
PubMed
DOI
PMC
ACKERMANN C, SMITS M, WOOST R, EBERHARD JM, PEINE S, KUMMER S, MARGET M, KUNTZEN T, KWOK W, LOHSE AW, JACOBS T, BOETTLER T, SCHULZE ZUR WIESCH J. HCV-specific CD4+ T cells of patients with acute and chronic HCV infection display high expression of TIGIT and other co-inhibitory molecules. Sci Rep. 2019;9:10624. doi: 10.1038/s41598-019-47024-8.
PubMed
DOI
PMC
AGRESTA L, HOEBE KHN, JANSSEN EM. The emerging role of CD244 signaling in immune cells of the tumor microenvironment. Front Immunol. 2018;9:2809. doi: 10.3389/fimmu.2018.02809.
PubMed
DOI
PMC
ALSAAB HO, SAU S, ALZHRANI R, TATIPARTI K, BHISE K, KASHAW SK, IYER AK. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561. doi: 10.3389/fphar.2017.00561.
PubMed
DOI
PMC
BARBER DL, WHERRY EJ, MASOPUST D, ZHU B, ALLISON JP, SHARPE AH, FREEMAN GJ, AHMED R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682–687. doi: 10.1038/nature04444.
PubMed
DOI
BERSANELLI M, GIANNARELLI D, CASTRIGNANÒ P, FORNARINI G, PANNI S, MAZZONI F, TISEO M, ROSSETTI S, GAMBALE E, ROSSI E, PAPA A, CORTELLINI A, LOLLI C, RATTA R, MICHIARA M, MILELLA M, De LUCA E, SORARÙ M, MUCCIARINI C, ATZORI F, BANNA GL, La TORRE L, ET AL. Influenza vaccine indication during therapy with immune checkpoint inhibitors: A transversal challenge. The INVIDIA study. Immunotherapy. 2018;10:1229–1239. doi: 10.2217/imt-2018-0080.
PubMed
DOI
BERSANELLI M. COVID-19 and the newly rediscovered multidisciplinarity. Immunotherapy. 2020;12:1101–1103. doi: 10.2217/imt-2020-0205.
PubMed
DOI
PMC
BLACKBURN SD, SHIN H, HAINING WN, ZOU T, WORKMAN CJ, POLLEY A, BETTS MR, FREEMAN GJ, VIGNALI DA, WHERRY EJ. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10:29–37. doi: 10.1038/ni.1679.
PubMed
DOI
PMC
BLANK CU, HAINING WN, HELD W, HOGAN PG, KALLIES A, LUGLI E, LYNN RC, PHILIP M, RAO A, RESTIFO NP, ET AL. Defining 'T cell exhaustion'. Nat Rev Immunol. 2019;19:665–674. doi: 10.1038/s41577-019-0221-9.
PubMed
DOI
PMC
BOBCAKOVA A, PETRISKOVA J, VYSEHRADSKY R, KOCAN I, KAPUSTOVA L, BARNOVA M, DIAMANT Z, JESENAK M. Immune profile in patients with COVID-19: Lymphocytes exhaustion markers in relationship to clinical outcome. Front Cell Infect Microbiol. 2021;11:646688. doi: 10.3389/fcimb.2021.646688.
PubMed
DOI
PMC
BONAM SR, KAVERI SV, SAKUNTABHAI A, GILARDIN L, BAYRY J. Adjunct immunotherapies for the management of severely ill COVID-19 patients. Cell Rep Med. 2020;1:100016. doi: 10.1016/j.xcrm.2020.100016.
PubMed
DOI
PMC
BONIFACIUS A, TISCHER-ZIMMERMANN S, DRAGON AC, GUSSAROW D, VOGEL A, KRETTEK U, GÖDECKE N, YILMAZ M, KRAFT ARM, HOEPER MM, ET AL. COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. Immunity. 2021;54:340–354.e6. doi: 10.1016/j.immuni.2021.01.008.
PubMed
DOI
PMC
BONOMI L, GHILARDI L, ARNOLDI E, TONDINI CA, BETTINI AC. A rapid fatal evolution of Coronavirus Disease-19 in a patient with advanced lung cancer with a long-time response to nivolumab. J Thorac Oncol. 2020;15:e83–e85. doi: 10.1016/j.jtho.2020.03.021.
PubMed
DOI
PMC
BRETON G, MENDOZA P, HÄGGLÖF T, OLIVEIRA TY, SCHAEFER-BABAJEW D, GAEBLER C, TURROJA M, HURLEY A, CASKEY M, NUSSENZWEIG MC. Persistent cellular immunity to SARS-CoV-2 infection. J Exp Med. 2021;218:e20202515. doi: 10.1084/jem.20202515.
PubMed
DOI
PMC
BUTLER NS, MOEBIUS J, PEWE LL, TRAORE B, DOUMBO OK, TYGRETT LT, WALDSCHMIDT TJ, CROMPTON PD, HARTY JT. Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat Immunol. 2011;13:188–4195. doi: 10.1038/ni.2180.
PubMed
DOI
PMC
CHAN JF, KOK KH, ZHU Z, CHU H, TO KK, YUAN S, YUEN KY. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9:221–236. doi: 10.1080/22221751.2020.1719902.
PubMed
DOI
PMC
CHANG HL, WEI PJ, WU KL, HUANG HL, YANG CJ. Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic. Lung Cancer. 2020;146:376–377. doi: 10.1016/j.lungcan.2020.06.013.
PubMed
DOI
PMC
CHEMNITZ JM, PARRY RV, NICHOLS KE, JUNE CH, RILEY JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004;173:945–954. doi: 10.4049/jimmunol.173.2.945.
PubMed
DOI
CHEN N, ZHOU M, DONG X, QU J, GONG F, HAN Y, QIU Y, WANG J, LIU Y, WEI Y, XIA J, YU T, ZHANG X, ZHANG L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395:507–513. doi: 10.1016/S0140-6736(20)30211-7.
PubMed
DOI
PMC
CHIAPPELLI F, KHAKSHOOY A, GREENBERG G. CoViD-19 immunopathology and immunotherapy. Bioinformation. 2020;16:219–222. doi: 10.6026/97320630016219.
PubMed
DOI
PMC
CORTESE I, MURANSKI P, ENOSE-AKAHATA Y, HA SK, SMITH B, MONACO M, RYSCHKEWITSCH C, MAJOR EO, OHAYON J, SCHINDLER MK, BECK E, REOMA LB, JACOBSON S, REICH DS, NATH A. Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med. 2019;380:1597–1605. doi: 10.1056/NEJMoa1815039.
PubMed
DOI
DAY CL, KAUFMANN DE, KIEPIELA P, BROWN JA, MOODLEY ES, REDDY S, MACKEY EW, MILLER JD, LESLIE AJ, DEPIERRES C, MNCUBE Z, DURAISWAMY J, ZHU B, EICHBAUM Q, ALTFELD M, WHERRY EJ, COOVADIA HM, GOULDER PJ, KLENERMAN P, AHMED R, FREEMAN GJ, WALKER BD. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443:350–354. doi: 10.1038/nature05115.
PubMed
DOI
DEMARIA O, CARVELLI J, BATISTA L, THIBULT ML, MOREL A, ANDRÉ P, MOREL Y, VÉLY F, VIVIER E. Identification of druggable inhibitory immune checkpoints on natural killer cells in COVID-19. Cell Mol Immunol. 2020;17:995–997. doi: 10.1038/s41423-020-0493-9.
PubMed
DOI
PMC
Di COSIMO S, MALFETTONE A, PÉREZ-GARCÍA JM, LLOMBART-CUSSAC A, MICELI R, CURIGLIANO G, CORTÉS J. Immune checkpoint inhibitors: A physiology-driven approach to the treatment of coronavirus disease 2019. Eur J Cancer. 2020;135:62–65. doi: 10.1016/j.ejca.2020.05.026.
PubMed
DOI
PMC
DIAO B, WANG C, TAN Y, CHEN X, LIU Y, NING L, CHEN L, LI M, LIU Y, WANG G, YUAN Z, FENG Z, ZHANG Y, WU Y, CHEN Y. Reduction and functional exhaustion of T cells in patients with Coronavirus Disease 2019 (COVID-19) Front Immunol. 2020;11:827. doi: 10.3389/fimmu.2020.00827.
PubMed
DOI
PMC
DIPASQUALE A, PERSICO P, LORENZI E, RAHAL D, SANTORO A, SIMONELLI M. COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report. J Immunother Cancer. 2021;9:e001870. doi: 10.1136/jitc-2020-001870.
PubMed
DOI
PMC
DOOKIE RS, VILLEGAS-MENDEZ A, KROEZE H, BARRETT JR, DRAPER SJ, FRANKE-FAYARD BM, JANSE CJ, MacDONALD AS, COUPER KN. Combinatorial Tim-3 and PD-1 activity sustains antigen-specific Th1 cell numbers during blood-stage malaria. Parasite Immunol. 2020;42:e12723. doi: 10.1111/pim.12723dookie.
PubMed
DOI
ELTANBOULY MA, ZHAO Y, SCHAAFSMA E, BURNS CM, MABAERA R, CHENG C, NOELLE RJ. VISTA: A target to manage the innate cytokine storm. Front Immunol. 2021;11:595950. doi: 10.3389/fimmu.2020.595950.
PubMed
DOI
PMC
FIFE BT, PAUKEN KE. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N Y Acad Sci. 2011;1217:45–59. doi: 10.1111/j.1749-6632.2010.05919.x.
PubMed
DOI
FILES JK, BOPPANA S, PEREZ MD, SARKAR S, LOWMAN KE, QIN K, STERRETT S, CARLIN E, BANSAL A, SABBAJ S, LONG DM, KUTSCH O, KOBIE J, GOEPFERT PA, ERDMANN N. Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection. J Clin Invest. 2021;131:e140491. doi: 10.1172/JCI140491.
PubMed
DOI
PMC
GAMBICHLER T, REUTHER J, SCHEEL CH, BECKER JC. On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19. J Immunother Cancer. 2020;8:e001145. doi: 10.1136/jitc-2020-001145.
PubMed
DOI
PMC
GARASSINO MC, WHISENANT JG, HUANG LC, TRAMA A, TORRI V, AGUSTONI F, BAENA J, BANNA G, BERARDI R, BETTINI AC, BRIA E, BRIGHENTI M, CADRANEL J, De TOMA A, CHINI C, CORTELLINI A, FELIP E, FINOCCHIARO G, GARRIDO P, GENOVA C, ET AL. COVID-19 in patients with thoracic malignancies (TERAVOLT): First results of an international, registry-based, cohort study. Lancet Oncol. 2020;21:914–922. doi: 10.1016/S1470-2045(20)30314-4.
PubMed
DOI
PMC
GIAMARELLOS-BOURBOULIS EJ, NETEA MG, ROVINA N, AKINOSOGLOU K, ANTONIADOU A, ANTONAKOS N, DAMORAKI G, GKAVOGIANNI T, ADAMI ME, KATSAOUNOU P, ET AL. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27:992–1000.e3. doi: 10.1016/j.chom.2020.04.009.
PubMed
DOI
PMC
GONZALEZ-CAO M, ANTONAZAS-BASA M, PUERTOLAS T, MUNOZ-CONSUELO E, MANZANO JL, CARRERA C, MARQUEZ-RODAS I, LOPEZ-CRIADO P, RODRIGUEZ-MORENO JF, GARCIA-CASTANO A, ET AL. Cancer immunotherapy does not increase the risk of death by COVID-19 in melanoma patients. MedRxiv. 2020 doi: 10.1101/2020.05.19.20106971.
DOI
GU D, AO X, YANG Y, CHEN Z, XU X. Soluble immune checkpoints in cancer: production, function and biological significance. J Immunother Cancer. 2018;6:132. doi: 10.1186/s40425-018-0449-0.
PubMed
DOI
PMC
GUAN WJ, NI ZY, HU Y, LIANG W-HOU, C-QHE J-X, LIU L, SHAN H, LEI C-L, HUI DSC, ET AL. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032.
PubMed
DOI
PMC
GUTIÉRREZ-BAUTISTA JF, RODRIGUEZ-NICOLAS A, ROSALES-CASTILLO A, JIMÉNEZ P, GARRIDO F, ANDERSON P, RUIZ-CABELLO F, LÓPEZ-RUZ MÁ. Negative clinical evolution in COVID-19 patients is frequently accompanied with an increased proportion of undifferentiated Th cells and a strong under representation of the Th1 subset. Front Immunol. 2020;11:596553. doi: 10.3389/fimmu.2020.596553.
PubMed
DOI
PMC
HARJUNPÄÄ H, GUILLEREY C. TIGIT as an emerging immune checkpoint. Clin Exp Immunol. 2020;200:108–119. doi: 10.1111/cei.13407.
PubMed
DOI
PMC
HASAN A, AL-OZAIRI E, AL-BAQSUMI Z, AHMAD R, AL-MULLA F. Cellular and humoral immune responses in Covid-19 and immunotherapeutic approaches. Immunotargets Ther. 2021;10:63–85. doi: 10.2147/ITT.S280706.
PubMed
DOI
PMC
HERRMANN M, SCHULTE S, WILDNER NH, WITTNER M, BREHM TT, RAMHARTER M, WOOST R, LOHSE AW, JACOBS T, SCHULZE ZUR WIESCH J. Analysis of co-inhibitory receptor expression in COVID-19 infection compared to acute Plasmodium falciparum malaria: LAG-3 and TIM-3 correlate with T cell activation and course of disease. Front Immunol. 2020;11:1870. doi: 10.3389/fimmu.2020.01870.
PubMed
DOI
PMC
HOTCHKISS RS, COLSTON E, YENDE S, ANGUS DC, MOLDAWER LL, CROUSER ED, MARTIN GS, COOPERSMITH CM, BRAKENRIDGE S, MAYR FB, PARK PK, YE J, CATLETT IM, GIRGIS IG, GRASELA DM. Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559) Crit Care Med. 2019;47:632–642. doi: 10.1097/CCM.0000000000003685.
PubMed
DOI
PMC
HOTCHKISS RS, COLSTON E, YENDE S, CROUSER ED, MARTIN GS, ALBERTSON T, BARTZ RR, BRAKENRIDGE SC, DELANO MJ, PARK PK, DONNINO MW, TIDSWELL M, MAYR FB, ANGUS DC, COOPERSMITH CM, MOLDAWER LL, CATLETT IM, GIRGIS IG, YE J, GRASELA DM. Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab. Intensive Care Med. 2019;45:1360–1371. doi: 10.1007/s00134-019-05704-z.
PubMed
DOI
HUANG CT, WORKMAN CJ, FLIES D, PAN X, MARSON AL, ZHOU G, HIPKISS EL, RAVI S, KOWALSKI J, LEVITSKY HI, POWELL JD, PARDOLL DM, DRAKE CG, VIGNALI DA. Role of LAG-3 in regulatory T cells. Immunity. 2004;21:503–513. doi: 10.1016/j.immuni.2004.08.010.
PubMed
DOI
HUARD B, PRIGENT P, TOURNIER M, BRUNIQUEL D, TRIEBEL F. CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol. 1995;25:2718–2721. doi: 10.1002/eji.1830250949.
PubMed
DOI
ISGRÒ MA, VITALE MG, CELENTANO E, NOCERINO F, PORCIELLO G, CURVIETTO M, MALLARDO D, MONTAGNESE C, RUSSO L, ZANALETTI N, AVALLONE A, PENSABENE M, De LAURENTIIS M, CENTONZE S, PIGNATA S, CANNELLA L, MORABITO A, CAPONIGRO F, BOTTI G, MASUCCI GV, ET AL. Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis. J Transl Med. 2021;19:132. doi: 10.1186/s12967-021-02798-2.
PubMed
DOI
PMC
JEANNET R, DAIX T, FORMENTO R, FEUILLARD J, FRANÇOIS B. Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression. Intensive Care Med. 2020;46:1769–1771. doi: 10.1007/s00134-020-06127-x.
PubMed
DOI
PMC
JESENAK M, BRNDIAROVA M, URBANCIKOVA I, RENNEROVA Z, VOJTKOVA J, BOBCAKOVA A, OSTRO R, BANOVCIN P. Immune parameters and COVID-19 infection - associations with clinical severity and disease prognosis. Front Cell Infect Microbiol. 2020;10:364. doi: 10.3389/fcimb.2020.00364.
PubMed
DOI
PMC
JONES RB, NDHLOVU LC, BARBOUR JD, SHETH PM, JHA AR, LONG BR, WONG JC, SATKUNARAJAH M, SCHWENEKER M, CHAPMAN JM, GYENES G, VALI B, HYRCZA MD, YUE FY, KOVACS C, SASSI A, LOUTFY M, HALPENNY R, PERSAD D, SPOTTS G, HECHT FM, CHUN TW, McCUNE JM, KAUL R, RINI JM, NIXON DF, OSTROWSKI MA. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med. 2008;205:2763–2779. doi: 10.1084/jem.20081398.
PubMed
DOI
PMC
JUBEL JM, BARBATI ZR, BURGER C, WIRTZ DC, SCHILDBERG FA. The role of PD-1 in acute and chronic infection. Front Immunol. 2020;11:487. doi: 10.3389/fimmu.2020.00487.
PubMed
DOI
PMC
KISIELOW M, KISIELOW J, CAPOFERRI-SOLLAMI G, KARJALAINEN K. Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells. Eur J Immunol. 2005;35:2081–2088. doi: 10.1002/eji.200526090.
PubMed
DOI
KLEBANOV N, PAHALYANTS V, MURPHY WS, THEODOSAKIS N, ZUBIRI L, MONINA KLEVENS R, KWATRA SG, LILLY E, REYNNOLDS KL, SEMENOV YR. Risk of COVID-19 in patients with cancer receiving immune checkpoint inhibitors. Oncologist. 2021;26:e898–e901. doi: 10.1002/onco.13768.
PubMed
DOI
PMC
KONG Y, WANG Y, WU X, HAN J, LI G, HUA M, HAN K, ZHANG H, LI A, ZENG H. Storm of soluble immune checkpoints associated with disease severity of COVID-19. Signal Transduct Target Ther. 2020;5:192. doi: 10.1038/s41392-020-00308-2.
PubMed
DOI
PMC
KURI-CERVANTES L, PAMPENA MB, MENG W, ROSENFELD AM, ITTNER CAG, WEISMAN AR, AGYEKUM RS, MATHEW D, BAXTER AE, VELLA LA, KUTHURU O, APOSTOLIDIS SA, BERSHAW L, DOUGHERTY J, GREENPLATE AR, PATTEKAR A, KIM J, HAN N, GOUMA S, WEIRICK ME, ET AL. Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci Immunol. 2020;5:eabd7114. doi: 10.1126/sciimmunol.abd7114.
PubMed
DOI
PMC
LEGAT A, SPEISER DE, PIRCHER H, ZEHN D, FUERTES MARRACO SA. Inhibitory receptor expression depends more dominantly on differentiation and activation than “exhaustion” of human CD8 T cells. Front Immunol. 2013;4:455. doi: 10.3389/fimmu.2013.00455.
PubMed
DOI
PMC
LI J, NI L, DONG C. Immune checkpoint receptors in cancer: redundant by design? Curr Opin Immunol. 2017;45:37–42. doi: 10.1016/j.coi.2017.01.001.
PubMed
DOI
LI M, GUO W, DONG Y, WANG X, DAI D, LIU X, WU Y, LI M, ZHANG W, ZHOU H, ZHANG Z, LIN L, KANG Z, YU T, TIAN C, QIN R, GUI Y, JIANG F, FAN H, HEISSMEYER V, SARAPULTSEV A, WANG L, LUO S, HU D. Elevated exhaustion levels of NK and CD8+ T cells as indicators for progression and prognosis of COVID-19 disease. Front Immunol. 2020;11:580237. doi: 10.3389/fimmu.2020.580237.
PubMed
DOI
PMC
LIAO M, LIU Y, YUAN J, WEN Y, XU G, ZHAO J, CHENG L, LI J, WANG X, WANG F, LIU L, AMIT I, ZHANG S, ZHANG Z. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020;8:842–844. doi: 10.1038/s41591-020-0901-9.
PubMed
DOI
LINES JL, PANTAZI E, MAK J, SEMPERE LF, O’CONNEL S, CEERAZ S, SURIAWINATA AA, YAN S, ERNSTOFF MS, NOELLE R. VISTA is an immune checkpoint molecule for human T cells. Cancer Res. 2014;74:1924–1932. doi: 10.1158/0008-5472.CAN-13-1504.
PubMed
DOI
PMC
LUCAS CL, WORKMAN CJ, BEYAZ S, LOCASCIO S, ZHAO G, VIGNALI DAA, SYKES M. LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L. Blood. 2011;117:5532–5540. doi: 10.1182/blood-2010-11-318675.
PubMed
DOI
PMC
LUO J, RIZVI H, EGGER JV, PREESHAGUL IR, WOLCHOK JD, HELLMANN MD. Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers. Cancer Discov. 2020;10:1121–1128. doi: 10.1158/2159-8290.CD-20-0596.
PubMed
DOI
PMC
MARTÍN-QUIRÓS A, MAROUN-EID C, AVENDAÑO-ORTIZ J, LOZANO-RODRÍGUEZ R, QUIROGA JV, TERRÓN V, MONTALBÁN-HERNÁNDEZ K, GARCÍA-GARRIDO MA, Del VAL EM, Del BALZO-CASTILLO A. Potential role of the galectin-9/TIM-3 axis in the disparate progression of SARS-CoV-2 in a married couple: A case report. Biomed Hub. 2021;6:48–58. doi: 10.1159/000514727.
PubMed
DOI
PMC
MARUHASHI T, SUGIURA D, OKAZAKI I, OKAZAKI T. LAG-3: from molecular functions to clinical applications. J Immunother Cancer. 2020;8:e001014. doi: 10.1136/jitc-2020-001014.
PubMed
DOI
PMC
McLANE LM, ABDEL-HAKEEM MS, WHERRY EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol. 2019;37:457–495. doi: 10.1146/annurev-immunol-041015-055318.
PubMed
DOI
MENACHERY VD, SCHÄFER A, BURNUM-JOHNSON KE, MITCHELL HD, EISFELD A, WALTERS KB, NICORA CD, PURVINE SO, CASEY CP, MONROE ME, WEITZ KK, STRATTON KG, WEBB-ROBERTSON BJM, GRALINSKI LE, METZ TO, SMITH RD, WATERS KM, SIMS AC, KAWAOKA Y, BARIC RS. MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape. Proc Natl Acad Sci U S A. 2018;115:E1012–E1021. doi: 10.1073/pnas.1706928115.
PubMed
DOI
PMC
MORITZ RKC, GUTZMER R, ZIMMER L, MEIER F, AHMED MS, SELL S, SCHLAAK M, KAPP F, SACHSE MM, HAFERKAMP S, WELZEL J, KÄHLER KC, WEICHENTHAL M. SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: A survey of the German ADOREG melanoma registry. Eur J Cancer. 2021;144:382–385. doi: 10.1016/j.ejca.2020.11.015.
PubMed
DOI
PMC
MUNN DH, MELLOR AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013;34:137–143. doi: 10.1016/j.it.2012.10.00.
PubMed
DOI
PMC
OTSUKI N, KAMIMURA Y, HASHIGUCHI M, AZUMA M. Expression and function of the B and T lymphocyte attenuator (BTLA/CD272) on human T cells. Biochem Biophys Res Commun. 2006;344:1121–1127. doi: 10.1016/j.bbrc.2006.03.242.
PubMed
DOI
PACES J, STRIZOVA Z, SMRZ D, CERNY J. COVID-19 and the immune system. Physiol Res. 2020;69:379–388. doi: 10.33549/physiolres.934492.
PubMed
DOI
PMC
PALA L, CONFORTI F, COCOROCCHIO E, FERRUCCI P, De PAS MT, STUCCHI S, REPETTO M, SAPONARA M, QUEIROLO P. Course of Sars-CoV2 infection in patients with cancer treated with anti-PD-1: A case presentation and review of the literature. Cancer Invest. 2021;39:9–14. doi: 10.1080/07357907.2020.1844893.
PubMed
DOI
PALMER BE, NEFF CP, LECUREUX J, EHLER A, DSOUZA M, REMLING-MULDER L, KORMAN AJ, FONTENOT AP, AKKINA R. In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice. J Immunol. 2013;190:211–219. doi: 10.4049/jimmunol.1201108.
PubMed
DOI
PMC
PARRY RV, CHEMNITZ JM, FRAUWIRTH KA, LANFRANCO AR, BRAUNSTEIN I, KOBAYASHI SV, LINSLEY PS, THOMPSON CB, RILEY JL. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25:9543–9553. doi: 10.1128/MCB.25.21.9543-9553.2005.
PubMed
DOI
PMC
PAUKEN KE, WHERRY EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36:265–276. doi: 10.1016/j.it.2015.02.008.
PubMed
DOI
PMC
PEZESHKI PS, REZAEI N. Immune checkpoint inhibition in COVID-19: risks and benefits. Expert Opin Biol Ther. 2021;21:1173–1179. doi: 10.1080/14712598.2021.1887131.
PubMed
DOI
PMC
RENDEIRO AF, CASANO J, VORKAS CK, SINGH H, MORALES A, DESIMONE RA, ELLSWORTH GB, SOAVE R, KAPADIA SN, SAITO K, BROWN CD, HSU JM, KYRIAKIDES C, CHIU S, CAPELLI LV, CACCIAPUOTI MT, TAM W, GALLUZZI L, SIMONSON PD, ELEMENTO O, SALVATORE M, INGHIRAMI G. Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. Life Sci Alliance. 2020;4:e202000955. doi: 10.26508/lsa.202000955.
PubMed
DOI
PMC
RIZZO P, VIECELI DALLA SEGA F, FORTINI F, MARRACINO L, RAPEZZI C, FERRARI R. COVID-19 in the heart and the lungs: could we “Notch” the inflammatory storm? Basic Res Cardiol. 2020;115:31. doi: 10.1007/s00395-020-0791-5.
PubMed
DOI
PMC
ROBILOTTI EV, BABADY NE, MEAD PA, ROLLING T, PEREZ-JOHNSTON R, BERNARDES M, BOGLER Y, CALDARARO M, FIGUEROA CJ, GLICKMAN MS, JOANOW A, KALTSAS A, LEE YJ, LUCCA A, MARIANO A, MORJARIA S, NAWAR T, PAPANICOLAOU GA, PREDMORE J, REDELMAN-SIDI G, ET AL. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020;26:1218–1223. doi: 10.1016/j.xcrm.2020.100016.
PubMed
DOI
PMC
ROGIERS A, PIRES DA SILVA I, TENTORI C, TONDINI CA, GRIMES JM, TRAGER MH, NAHM S, ZUBIRI L, MANOS M, BOWLING P, ELKRIEF A, PAPNEJA N, VITALE MG, ROSE AN, BORGERS JSW, ROY S, MANGANA S, PIMENTEL MUNIZ T, COOKSLEY T, ET AL. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. J Immunother Cancer. 2021;9:e001931. doi: 10.1136/jitc-2020-001931.
PubMed
DOI
PMC
ROTZ SJ, LEINO D, SZABO S, MANGINO JL, TURPIN BK, PRESSEY JG. Severe cytokine release syndrome in a patient receiving PD-1-directed therapy. Pediatr Blood Cancer. 2017;64:e26642. doi: 10.1002/pbc.26642.
PubMed
DOI
ROWSHANRAVAN B, HALLIDAY N, SANSOM DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131:58–67. doi: 10.1182/blood-2017-06-74103.
PubMed
DOI
PMC
SAHEB SHARIF-ASKARI N, SAHEB SHARIF-ASKARI F, MDKHANA B, Al HEIALY S, ALSAFAR HS, HAMOUDI R, HAMID Q, HALWANI R. Enhanced expression of immune checkpoint receptors during SARS-CoV-2 viral infection. Mol Ther Methods Clin Dev. 2021;20:109–121. doi: 10.1016/j.omtm.2020.11.002.
PubMed
DOI
PMC
SHAH KP, SONG H, YE F, MOSLEHI JJ, BALKO JM, SALEM JE, JOHNSON DB. Demographic factors associated with toxicity in patients treated with anti-programmed cell death-1 therapy. Cancer Immunol Res. 2020;8:85955. doi: 10.1158/2326-6066.
PubMed
DOI
PMC
SHAHBAZI M, MOULANA Z, SEPIDARKISH M, BAGHERZADEH M, REZANEJAD M, MIRZAKHANI M, JAFARI M, MOHAMMADNIA-AFROUZI M. Pronounce expression of Tim-3 and CD39 but not PD1 defines CD8 T cells in critical Covid-19 patients. Microb Pathog. 2021;153:104779. doi: 10.1016/j.micpath.2021.104779.
PubMed
DOI
PMC
SHEN C, LI Q, WEI Y, LI Y, LI J, TAO J. Management of immune checkpoint therapy for patients with cancer in the face of COVID-19. J Immunnother Cancer. 2020;8:e001593. doi: 10.1136/jitc-2020-001593.
PubMed
DOI
PMC
SHI Y, WANG Y, SHAO C, HUANG J, GAN J, HUANG X, BUCCI E, PIACENTINI M, IPPOLITO G, MELINO G. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27:1451–1454. doi: 10.1038/s41418-020-0530-3.
PubMed
DOI
PMC
SCHULTHEIß C, PASCHOLD L, SIMNICA D, MOHME M, WILLSCHER E, Von WENSERSKI L, SCHOLZ R, WIETERS I, DAHLKE C, TOLOSA E, SEDDING DG, CIESEK S, ADDO M, BINDER M. Next-generation sequencing of T and B cell receptor repertoires from COVID-19 patients showed signatures associated with severity of disease. Immunity. 2020;53:442–455.e4. doi: 10.1016/j.immuni.2020.06.024.
PubMed
DOI
PMC
STARON MM, GRAY SM, MARSHALL HD, PARISH IA, CHEN JH, PERRY CJ, CUI G, LI MO, KAECH SM. The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. Immunity. 2014;41:802–814. doi: 10.1016/j.immuni.2014.10.013.
PubMed
DOI
PMC
SULLIVAN RJ, JOHNSON DB, RINI BI, NEILAN TG, LOVLY CM, MOSLEHI JJ, REYNOLDS KL. COVID-19 and immune checkpoint inhibitors: initial considerations. J Immunother Cancer. 2020;8:e000933. doi: 10.1136/jitc-2020-000933.
PubMed
DOI
PMC
SYN NL, TENG MWL, MOK TSK, SOO RA. De-novo acquired resistance to immune checkpoint tageting. Lancet Oncol. 2017;18:e731–e741. doi: 10.1016/s1470-2045(17)30607-1.
PubMed
DOI
TAKAMURA S, TSUJI-KAWAHARA S, YAGITA H, AKIBA H, SAKAMOTO M, CHIKAISHI T, KATO M, MIYAZAWA M. Premature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors. J Immunol. 2010;184:4696–4707.
https://doi.org/0.4049/jimmunol.0903478
.
PubMed
TAN L, WANG Q, ZHANG D, DING J, HUANG Q, TANG YQ, WANG Q, MIAO H. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020;5:33. doi: 10.1038/s41392-020-0148-4.
PubMed
DOI
PMC
TAYLOR PM, ASKONAS BA. Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. Immunology. 1986;58:417–420.
PubMed
PMC
TOMIĆ S, ĐOKIĆ J, STEVANOVIĆ D, ILLIĆ N, GRUDEN-MOVSESIJAN A, DINIĆ M, RADOJEVIĆ D, BEKIĆ M, MITROVIĆ N, TOMAŠEVIĆ R, MIKIĆ D, STOJANIVIĆ D, ČOLIĆ M. Reduced expression of autophagy markers and expansion of myeloid-derived suppressor cells correlate with poor T cell response in severe COVID-19 patients. Front Immunol. 2021;12:614599. doi: 10.3389/fimmu.2021.614599.
PubMed
DOI
PMC
TOOR SM, SALEH R, SASIDHARAN NAIR V, TAHA RZ, ELKORD E. T-cell responses and therapies against SARS-CoV-2 infection. Immunology. 2021;162:30–43. doi: 10.1111/imm.13262.
PubMed
DOI
PMC
TRIEBEL F, JITSUKAWA S, BAIXERAS E, ROMAN-ROMAN S, GENEVEE C, VIEGAS-PEQUIGNOT E, HERCEND T. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med. 1990;171:1393–1405. doi: 10.1084/jem.171.5.1393.
PubMed
DOI
PMC
VARCHETTA S, MELE D, OLIVIERO B, MANTOVANI S, LUDOVISI S, CERINO A, BRUNO R, CASTELLI A, MOSCONI M, VECCHIA M, RODA S, SACHS M, KLERSY C, MONDELLI MU. Unique immunological profile in patients with COVID-19. Cell Mol Immunol. 2021;18:604–612. doi: 10.1038/s41423-020-00557-9.
PubMed
DOI
PMC
VAŠKŮ A. Covid-19 infection and the host genetic predisposition: does it exist? Physiol Res. 2020;69:511–514. doi: 10.33549/physiolres.934504.
PubMed
DOI
PMC
VIVARELLI S, FALZONE L, TORINO F, SCANDURRA G, RUSSO G, BORDONARO R, PAPPALARDO F, SPANDIDOS DA, RACITI G, LIBRA M. Immune-checkpoint inhibitors from cancer to COVID 19: A promising avenue for the treatment of patients with COVID 19 (Review) Int J Oncol. 2021;58:145–157. doi: 10.3892/ijo.2020.5159.
PubMed
DOI
PMC
WORKMAN CJ, DUGGER KJ, VIGNALI DA. Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3. J Immunol. 2002;169:5392–5395. doi: 10.4049/jimmunol.169.10.5392.
PubMed
DOI
WORKMAN CJ, VIGNALI DA. The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur J Immunol. 2003;33:970–979. doi: 10.1002/eji.200323382.
PubMed
DOI
WORKMAN CJ, WANG Y, EL KASMI KC, PARDOLL DM, MURRAY PJ, DRAKE CG, VIGNALI DA. LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol. 2009;182:1885–1891. doi: 10.4049/jimmunol.0800185.
PubMed
DOI
PMC
WU C, CHEN X, CAI Y, XIA J, ZHOU X, XU S, HUANG H, ZHANG L, ZHOU X, DU C, ZHANG Y, SONG J, WANG S, CHAO Y, YANG Z, XU J, ZHOU X, CHEN D, XIONG W, XU L, ZHOU F, JIANG J, BAI C, ZHENG J, SONG Y. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934–943. doi: 10.1001/jamainternmed.2020.0994.
PubMed
DOI
PMC
ZHANG B, ZHOU X, QIU Y, SONG Y, FENG F, FENG J, SONG Q, JIA Q, WANG J. Clinical characteristics of 82 cases of death from COVID-19. PLoS One. 2020;15:e0235458. doi: 10.1371/journal.pone.0235458.
PubMed
DOI
PMC
ZHENG HY, ZHANG M, YANG CX, ZHANG N, WANG XC, YANG XP, DONG XD, ZHENG YT. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020;17:541–543. doi: 10.1038/s41423-020-0401-3.
PubMed
DOI
PMC
ZHENG M, GAO Y, WANG G, SONG G, LIU S, SUN D, XU Y, TIAN Z. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17:533–535. doi: 10.1038/s41423-020-0402-2.
PubMed
DOI
PMC